ClinicalTrials.gg
Status unknownNCT03415360Updated Sep 25, 2018

Cryolesion in Treatment of Phantom Limb Pain

An interventional study of cryoablation in Phantom Limb Pain, Stump Neuralgia and Pain, Phantom, sponsored by Military Institute od Medicine National Research Institute. Status unknown at 1 site in Poland. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-09-25.

Sponsored by Military Institute od Medicine National Research Institute · Not applicable, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Sep 2018), so the status shown — last known as Recruiting — may be out of date.
Phase
Not applicable
Study type
Interventional
Enrollment
50
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

Assessment of pain intensity on the NRS. Assessment of the quality of life by SF-36 and AIS. Diagnostic/prognostic nerve block with 5 ml of 2% lidocaine under real-time ultrasound control with confirmation of the correct position of the needle using a peripheral nerve stimulator.

Reassessment of pain intensity on the NRS 30 minutes after local anesthetic block.

Cryoablation under real-time ultrasound control if the NRS value is reduced by ≥ 2 points.

If pain intensity on the NRS reduced by less than 2 points, reassessment 60 minutes after local anesthetic block.

Cryoablation under real-time ultrasound control if the NRS value is reduced by ≥ 2 points.

If pain intensity on the NRS reduces by less than 2 points 60 minutes after local anesthetic block cryoablation will not be performed.

Cryoablation effect will be evaluated 24 hours, 7 days, 30 days, 3 months, 6 months post procedure.

  • 24 hours after the procedure - assessment of pain intensity and quality of life
  • 7 days after the procedure - assessment of pain intensity
  • 30 days after the procedure - assessment of pain intensity and quality of life
  • 3 months after the procedure - assessment of pain intensity
  • 6 months after the procedure - assessment of pain intensity and quality of
02

Conditions studied

  • Phantom Limb Pain
  • Stump Neuralgia
  • Pain, Phantom

Keywords

  • cryoablation
03

In context

Phantom Limb

163 studies on the registry are indexed under Phantom Limb; 35 are open to participants now.

This study's planned enrollment of 50 is above the median of 30 across 125 interventional studies indexed under Phantom Limb.

Browse Phantom Limb studies →

Lead sponsor

Military Institute od Medicine National Research Institute is the lead sponsor of 45 studies on the registry; 6 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Status post amputation of a lower or upper limb
  • Pain related to amputation as determined by referring physician and investigator
  • of patient to enter the study
  • Reduction of pain after the diagnostic/prognostic anesthetic block of the relevant main peripheral nerves under ultrasonography guidance in an analogous fashion to the cryoablation procedure

Exclusion criteria

Exclusion Criteria:

  • Pregnancy
  • Active infection in the area of the planned intervention
  • Blood coagulation disorders
  • Significant spinal stenosis or spinal anomalies that result in differential nerve root pressures
  • Significant disease or disorder that in the opinion of the Principal Investigator would preclude the safe performance of the anesthetic block or cryoablation
  • Participation in another trial involving systemic administration of agents of unknown chemical composition.
  • No reduction of pain after the diagnostic block of the relevant main peripheral nerves
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
50 participants (estimated)

Study arms

  • Other
    cryoablation

    peripheral nerve cryoablation

    Procedure: cryoablation

Interventions

  • Procedurecryoablation

    cryoablation of nerve responsible for phantom limb pain

06

What researchers measure

Primary outcomes

  1. Reduction of pain

    Assessment of pain intensity pre- and post - cryoablation on the NRS (numeric rating scale). Numeric Rating Scale (NRS) is a unidimensional measure of pain intensity in adults. This is a 11-point numeric scale ranges from '0' (minimum, "no pain") to '10' (maximum, "pain as bad as one can imagine"). The lower the NRS value, the better clinical outcome.

    Time frame: T1: before cryoablation; T2: 24 hours after cryoablation; T3: 7 days after cryoablation; T4: 30 days after cryoablation; T5: 3 months after cryoablation; T6: 6 months after cryoablation.

Secondary outcomes

  1. The quality of life (SF-36)

    Assessment of the quality of life pre- and post - cryoablation on SF-36. 36-Item Short Form Survey (SF-36) is a 36-item questionnaire which measures quality of life across eight domains: physical functioning, role limitations due to physical health, role limitations due to emotional problems, energy/fatigue, emotional well-being, social functioning, pain, and general health. For each of the eight domains that the SF36 measures an aggregate percentage score is produced. The percentage scores range from 0% (lowest or worst possible level of functioning) to 100% (highest or best possible level of functioning).

    Time frame: A1: before cryoablation; A2: 24 hours after cryoablation; A3: 30 days after cryoablation; A4: 6 months after cryoablation.

  2. The quality of life (AIS)

    Assessment of the quality of life pre- and post - cryoablation on AIS. The Acceptance of Illness Scale (AIS) consists of eight statements describing negative impact of poor health status and its consequences for patients' functioning. The scoring for each statement varies from 1 (poor adaptation to the disease) to 5 (full acceptance of the disease). The total score ranges between 8 and 40. The lower score, the poorer acceptance of disease and more severe restrictions caused by condition. A high score means acceptance of patient's own health status and lack of negative emotions related to illness.

    Time frame: A1: before cryoablation; A2: 24 hours after cryoablation; A3: 30 days after cryoablation; A4: 6 months after cryoablation.

07

Study locations

1 of 1 sites recruiting
  • Military Institute of Medicine
    Warsaw, 04141, Poland
    Recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2018 (actual). Primary completion is estimated for Jun 2019, 16 months after the start.

Of 61 non-industry interventional studies with no phase under Phantom Limb, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 47. This study's planned 16 months is below that.

Counting every sponsor, half of 64 studies reached it within 34 months; a quarter within 13 and three quarters within 50.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 13, 2018
First posted
Jan 30, 2018
StartActual
Feb 9, 2018
Primary completionEst.
Jun 2019
CompletionEst.
Jan 2020
Last update
Sep 25, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 25, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT03415360
Lead sponsor
Military Institute od Medicine National Research Institute
Responsible party
Dariusz Tomaszewski (Adjunct professor, Military Institute od Medicine National Research Institute) — Principal investigator
First posted
Jan 30, 2018
Start date
Feb 9, 2018
Primary completion
Jun 2019 (estimated)
Completion
Jan 2020 (estimated)
Last update
Sep 25, 2018

Study contacts

Dariusz Tomaszewski, MD PhD
Contact
dtomaszewski@wim.mil.pl
00 48501 190 386
Jaroslaw J Les, MD PhD
Contact
jles@wim.mil.pl
00 48 695 926 026
Dariusz Tomaszewski
study chair · Military Institute of Medicine

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Sep 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion